

EQA round: APLA2/22 - Antiphospholipid Antibodies

Deadline: 30.09.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
(461) anti-cardiolipin screening				
A	(38) IL	>>>	1 Positive	6,3 %
	(135) OrgenTec	>>>	12 Positive	75 %
	(148) Aesku.lab Diagnostika	>>>	3 Positive	19 %
----- Total per sample: n = 16		-----	Success: 100 %	-----
B	(38) IL	>>>	1 Positive	6,3 %
	(135) OrgenTec	>>>	12 Positive	75 %
	(148) Aesku.lab Diagnostika	>>>	3 Positive	19 %
----- Total per sample: n = 16		-----	Success: 100 %	-----
Total success: 100 %				

(463) anti-cardiolipin IgG

A	(5) Dialab	>>>	1 Positive	1,6 %
	(14) Bio-Rad	>>>	1 Positive	1,6 %
	(32) Human		1 Negative	1,6 %
	(38) IL	>>>	3 Positive	4,7 %
	(49) BioVendor	>>>	2 Positive	3,1 %
	(87) Euroimmun	>>>	7 Positive	11 %
	(115) BioSystems	>>>	1 Positive	1,6 %
	(135) OrgenTec	>>>	18 Positive	28 %
	(139) BL Diagnostics	>>>	1 Positive	1,6 %
	(148) Aesku.lab Diagnostika	>>>	5 Positive	7,8 %
	(166) Thermo Fisher	>>>	6 Positive	9,4 %
	(183) Immunodiagnostic Systems	>>>	2 Positive	3,1 %
	(211) INOVA Diagnostics	>>>	13 Positive	20 %
	(999) another manufacturer	>>>	3 Positive	4,7 %
----- Total per sample: n = 64		-----	Success: 98 %	-----
B	(5) Dialab	>>>	1 Positive	1,6 %
	(14) Bio-Rad	>>>	1 Positive	1,6 %
	(32) Human		1 Negative	1,6 %
	(38) IL	>>>	3 Positive	4,7 %
	(49) BioVendor	>>>	2 Positive	3,1 %
	(87) Euroimmun	>>>	7 Positive	11 %
	(115) BioSystems	>>>	1 Positive	1,6 %
	(135) OrgenTec	>>>	18 Positive	28 %
	(139) BL Diagnostics	>>>	1 Positive	1,6 %
	(148) Aesku.lab Diagnostika	>>>	5 Positive	7,8 %
	(166) Thermo Fisher	>>>	6 Positive	9,4 %
	(183) Immunodiagnostic Systems	>>>	2 Positive	3,1 %
	(211) INOVA Diagnostics	>>>	13 Positive	20 %
	(999) another manufacturer	>>>	3 Positive	4,7 %
----- Total per sample: n = 64		-----	Success: 98 %	-----
Total success: 98 %				

(464) anti-cardiolipin IgM

A	(5) Dialab	>>>	1 Negative	1,6 %
	(14) Bio-Rad	>>>	1 Negative	1,6 %
	(32) Human	>>>	1 Negative	1,6 %
	(38) IL	>>>	3 Negative	4,8 %
	(49) BioVendor	>>>	2 Negative	3,2 %
	(87) Euroimmun	>>>	7 Negative	11 %
	(115) BioSystems	>>>	1 Negative	1,6 %
	(135) OrgenTec	>>>	18 Negative	29 %
	(139) BL Diagnostics	>>>	1 Negative	1,6 %
	(148) Aesku.lab Diagnostika	>>>	5 Negative	7,9 %
	(166) Thermo Fisher	>>>	6 Negative	9,5 %
	(183) Immunodiagnostic Systems	>>>	2 Negative	3,2 %
	(211) INOVA Diagnostics	>>>	12 Negative	19 %
	(999) another manufacturer	>>>	3 Negative	4,8 %
----- Total per sample: n = 63		-----	Success: 100 %	-----
B	(5) Dialab	>>>	1 Negative	1,6 %
	(14) Bio-Rad	>>>	1 Negative	1,6 %
	(32) Human	>>>	1 Negative	1,6 %
	(38) IL	>>>	3 Negative	4,8 %
	(49) BioVendor	>>>	2 Negative	3,2 %
	(87) Euroimmun	>>>	7 Negative	11 %

Test			N	Result	N _{rel}
Sample	Group				
B	(115) BioSystems	>>>	1	Negative	1,6 %
	(135) OrgenTec	>>>	18	Negative	29 %
	(139) BL Diagnostics	>>>	1	Negative	1,6 %
	(148) Aesku.lab Diagnostika	>>>	5	Negative	7,9 %
	(166) Thermo Fisher	>>>	6	Negative	9,5 %
	(183) Immunodiagnostic Systems	>>>	2	Negative	3,2 %
	(211) INOVA Diagnostics	>>>	12	Negative	19 %
	(999) another manufacturer	>>>	3	Negative	4,8 %
Total per sample: n = 63		Success: 100 %			
Total success: 100 %					

(465) anti-beta2-GP 1 screening

A	(5) Dialab	>>>	1	Positive	7,1 %
	(38) IL	>>>	1	Positive	7,1 %
	(49) BioVendor	>>>	1	Positive	7,1 %
	(135) OrgenTec	>>>	9	Positive	64 %
	(148) Aesku.lab Diagnostika	>>>	2	Positive	14 %
Total per sample: n = 14		Success: 100 %			
B	(5) Dialab	>>>	1	Positive	7,1 %
	(38) IL	>>>	1	Positive	7,1 %
	(49) BioVendor	>>>	1	Positive	7,1 %
	(135) OrgenTec	>>>	9	Positive	64 %
	(148) Aesku.lab Diagnostika	>>>	2	Positive	14 %
Total per sample: n = 14		Success: 100 %			
Total success: 100 %					

(467) anti-beta2-GP 1 IgG

A	(14) Bio-Rad	>>>	1	Positive	1,7 %
	(32) Human	>>>	1	Positive	1,7 %
	(38) IL	>>>	4	Positive	6,7 %
	(49) BioVendor	>>>	1	Positive	1,7 %
	(87) Euroimmun	>>>	7	Positive	12 %
	(135) OrgenTec	>>>	20	Positive	33 %
	(139) BL Diagnostics	>>>	1	Positive	1,7 %
	(148) Aesku.lab Diagnostika	>>>	4	Positive	6,7 %
	(166) Thermo Fisher	>>>	5	Positive	8,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	1,7 %
	(211) INOVA Diagnostics	>>>	13	Positive	22 %
	(999) another manufacturer	>>>	2	Positive	3,3 %
Total per sample: n = 60		Success: 100 %			
B	(14) Bio-Rad	>>>	1	Positive	1,7 %
	(32) Human	>>>	1	Positive	1,7 %
	(38) IL	>>>	4	Positive	6,7 %
	(49) BioVendor	>>>	1	Positive	1,7 %
	(87) Euroimmun	>>>	7	Positive	12 %
	(135) OrgenTec	>>>	20	Positive	33 %
	(139) BL Diagnostics	>>>	1	Positive	1,7 %
	(148) Aesku.lab Diagnostika	>>>	1	Negative	1,7 %
		>>>	3	Positive	5,0 %
	(166) Thermo Fisher	>>>	5	Positive	8,3 %
	(183) Immunodiagnostic Systems	>>>	1	Positive	1,7 %
	(211) INOVA Diagnostics	>>>	13	Positive	22 %
	(999) another manufacturer	>>>	2	Positive	3,3 %
Total per sample: n = 60		Success: 98 %			
Total success: 98 %					

(468) anti-beta2-GP 1 IgM

A	(14) Bio-Rad	>>>	1	Negative	1,7 %
	(32) Human	>>>	1	Negative	1,7 %
	(38) IL	>>>	4	Negative	6,8 %
	(49) BioVendor	>>>	1	Negative	1,7 %
	(87) Euroimmun	>>>	6	Negative	10 %
	(135) OrgenTec	>>>	20	Negative	34 %
	(139) BL Diagnostics	>>>	1	Negative	1,7 %
	(148) Aesku.lab Diagnostika	>>>	4	Negative	6,8 %
	(166) Thermo Fisher	>>>	5	Negative	8,5 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	1,7 %
	(211) INOVA Diagnostics	>>>	13	Negative	22 %
	(999) another manufacturer	>>>	2	Negative	3,4 %
Total per sample: n = 59		Success: 100 %			

Summary statistics - qualitative results

(Groups: manufacturer of kit)

EQA round: APLA2/22 - Antiphospholipid Antibodies

Deadline: 30.09.2022

Test			N	Result	N _{rel}
Sample	Group				
B	(14) Bio-Rad	>>>	1	Negative	1,7 %
	(32) Human	>>>	1	Negative	1,7 %
	(38) IL	>>>	4	Negative	6,8 %
	(49) BioVendor	>>>	1	Negative	1,7 %
	(87) Euroimmun	>>>	6	Negative	10 %
	(135) OrgenTec	>>>	20	Negative	34 %
	(139) BL Diagnostics	>>>	1	Negative	1,7 %
	(148) Aesku.lab Diagnostika	>>>	4	Negative	6,8 %
	(166) Thermo Fisher	>>>	5	Negative	8,5 %
	(183) Immunodiagnostic Systems	>>>	1	Negative	1,7 %
	(211) INOVA Diagnostics	>>>	13	Negative	22 %
	(999) another manufacturer	>>>	2	Negative	3,4 %
Total per sample: n = 59		Success: 100 %			
Total success: 100 %					

st_kl

End of report

Printed: 07.10.2022